


Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently amended) A compound of formula (I) or a pharmaceutically acceptable salt thereof:



(I)

in which

$\text{R}^1$  is hydrogen, halogen, CN, nitro,  $\text{SO}_2\text{R}^4$ , OH,  $\text{OR}^4$ ,  $\text{S(O)}_x\text{R}^4$ ,  $\text{SO}_2\text{NR}^5\text{R}^6$ ,  $\text{CONR}^5\text{R}^6$ ,  $\text{NR}^5\text{R}^6$ , aryl (optionally substituted by chlorine or fluorine),  $\text{C}_2\text{-C}_6$  alkenyl,  $\text{C}_2\text{-C}_6$  alkynyl or  $\text{C}_{1-6}$  alkyl, the latter three groups being optionally substituted by one or more substituents independently selected from halogen,  $\text{OR}^8$  and  $\text{NR}^5\text{R}^6$ ,  $\text{S(O)}_x\text{R}^7$  where x is 0, 1 or 2;

$\text{R}^2$  is hydrogen, halogen, CN,  $\text{SO}_2\text{R}^4$  or  $\text{CONR}^5\text{R}^6$ ,  $\text{CH}_2\text{OH}$ ,  $\text{CH}_2\text{OR}^4$  or  $\text{C}_{1-7}$  alkyl, the latter group being optionally substituted by one or more substituents independently selected from halogen atoms,  $\text{OR}^8$  and  $\text{NR}^5\text{R}^6$ ,  $\text{S(O)}_x\text{R}^7$  where x is 0, 1 or 2;

$\text{R}^3$  is aryl or heteroaryl each of which is optionally substituted by one or more substituents independently selected from hydrogen, halogen, CN, nitro, OH,  $\text{SO}_2\text{R}^4$ ,  $\text{OR}^4$ ,  $\text{SR}^4$ ,  $\text{SOR}^4$ ,  $\text{SO}_2\text{NR}^5\text{R}^6$ ,  $\text{CONR}^5\text{R}^6$ ,  $\text{NR}^5\text{R}^6$ ,  $\text{NHCOR}^4$ ,  $\text{NH}\text{SO}_2\text{R}^4$ ,  $\text{NH}\text{CO}_2\text{R}^4$ ,  $\text{NR}^7\text{SO}_2\text{R}^4$ ,  $\text{NR}^7\text{CO}_2\text{R}^4$ ,  $\text{C}_2\text{-C}_6$

alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, C<sub>1-6</sub> alkyl, the latter three groups being optionally substituted by one or more substituents independently selected from halogen atoms, OR<sup>8</sup> and NR<sup>5</sup>R<sup>6</sup>, S(O)<sub>x</sub>R<sup>7</sup> where x = 0,1 or 2;

R<sup>4</sup> represents aryl, heteroaryl, or C<sub>1-6</sub>alkyl all of which may be optionally substituted by one or more substituents independently selected from halogen atoms, aryl, heteroaryl, OR<sup>10</sup>, OH, NR<sup>11</sup>R<sup>12</sup>, S(O)<sub>x</sub>R<sup>13</sup> (where x = 0,1 or 2), CONR<sup>14</sup>R<sup>15</sup>, NR<sup>14</sup>COR<sup>15</sup>, SO<sub>2</sub>NR<sup>14</sup>R<sup>15</sup>, NR<sup>14</sup>SO<sub>2</sub>R<sup>15</sup>, CN, nitro;

R<sup>5</sup> and R<sup>6</sup> independently represent a hydrogen atom, a C<sub>1-6</sub>alkyl group, or an aryl, or a heteroaryl, the latter three of which may be optionally substituted by one or more substituents independently selected from halogen atoms, aryl, OR<sup>8</sup> and NR<sup>14</sup>R<sup>15</sup>, CONR<sup>14</sup>R<sup>15</sup>, NR<sup>14</sup>COR<sup>15</sup>, SO<sub>2</sub>NR<sup>14</sup>R<sup>15</sup>, NR<sup>14</sup>SO<sub>2</sub>R<sup>15</sup>; CN, nitro

or

R<sup>5</sup> and R<sup>6</sup> together with the nitrogen atom to which they are attached can form a 3-8 membered saturated heterocyclic ring optionally containing one or more atoms selected from O, S(O)<sub>x</sub> where x = 0,1 or 2, NR<sup>16</sup>, and itself optionally substituted by C<sub>1-3</sub> alkyl;

R<sup>7</sup> and R<sup>13</sup> independently represent a C<sub>1</sub>-C<sub>6</sub>, alkyl, an aryl or a heteroaryl group, all of which may be optionally substituted by halogen atoms;

R<sup>8</sup> represents a hydrogen atom, C(O)R<sup>9</sup>, C<sub>1</sub>-C<sub>6</sub> alkyl (optionally substituted by halogen atoms or aryl) an aryl or a heteroaryl group (optionally substituted by halogen);

each of R<sup>9</sup> R<sup>10</sup>, R<sup>11</sup>, R<sup>12</sup>, R<sup>14</sup>, R<sup>15</sup>, independently represents a hydrogen atom, C<sub>1</sub>-C<sub>6</sub> alkyl, an aryl or a heteroaryl group; and

R<sup>16</sup> is hydrogen, C<sub>1-4</sub> alkyl, -COC<sub>1-4</sub> alkyl, COYC<sub>1-4</sub>alkyl where Y is O or NR<sup>7</sup>.

each of R<sup>9</sup> R<sup>10</sup>, R<sup>11</sup>, R<sup>12</sup>, R<sup>14</sup>, R<sup>15</sup>, independently represents a hydrogen atom, C<sub>1</sub>-C<sub>6</sub> alkyl, an aryl or a heteroaryl group (all of which may be optionally substituted by halogen atoms); and

R<sup>16</sup> is hydrogen, C<sub>1-4</sub> alkyl, -COC<sub>1-4</sub> alkyl, COYC<sub>1-4</sub>alkyl where Y is O or NR<sup>7</sup>.

In the context of the present specification, unless otherwise indicated, an alkyl or alkenyl group or an alkyl or alkenyl moiety in a substituent group may be linear, branched or cyclic;

wherein the compound of formula (I) is not (2-methyl-3-(2-nitrophenylthio)-1-indolyl)acetic acid.

2. (Original) A compound according to claim 1 in which R<sup>1</sup> is aryl, hydrogen, methyl, chloro, fluoro, nitrile, nitro, bromo, iodo, SO<sub>2</sub>Me, SO<sub>2</sub>Et, NR<sup>4</sup>R<sup>5</sup>, SO<sub>2</sub>N-alkyl<sub>2</sub>.
3. (Previously presented) A compound according to claim 1 in which R<sup>2</sup> is C<sub>1-6</sub>alkyl.
4. (Original) A compound according to claim 3 in which R<sup>3</sup> is quinolyl, phenyl or thiazole substituted by one or more fluorine, chlorine, methyl, ethyl, isopropyl, methoxy, SO<sub>2</sub>Me, trifluoromethyl or aryl groups.
5. (Original) A compound according to claim 1 selected from:
  - 3-[(4-chlorophenyl)thio]-2,5-dimethyl-1*H*-indol-1-acetic acid;
  - 3-[(2-chloro-4-fluorophenyl)thio]-2,5-dimethyl-1*H*-indol-1-acetic acid;
  - 3-[(3-chloro-4-fluorophenyl)thio]-2,5-dimethyl-1*H*-indol-1-acetic acid;
  - 3-[(2-methoxyphenyl)thio]-2,5-dimethyl-1*H*-indol-1-acetic acid;
  - 3-[(3-fluorophenyl)thio]-2,5-dimethyl-1*H*-indol-1-acetic acid;
  - 3-[(4-ethylphenyl)thio]-2,5-dimethyl-1*H*-indol-1-acetic acid;
  - 3-[(2-chlorophenyl)thio]-2,5-dimethyl-1*H*-indol-1-acetic acid;
  - 3-[(2,5-dichlorophenyl)thio]-2,5-dimethyl-1*H*-indol-1-acetic acid;
  - 3-[(4-fluorophenyl)thio]-2,5-dimethyl-1*H*-indol-1-acetic acid;
  - 3-[(4-chloro-2-methylphenyl)thio]-2,5-dimethyl-1*H*-indol-1-acetic acid;
  - 3-[(4-chlorophenyl)thio]-4-cyano-2,5-dimethyl-1*H*-indole-1-acetic acid;
  - 5-chloro-3-[(4-chlorophenyl)thio]-6-cyano-2-methyl-1*H*-indole-1-acetic acid;
  - 3-[(4-chlorophenyl)thio]-4-(ethylsulfonyl)-7-methoxy-2-methyl-1*H*-indole-1-acetic acid;


3-[(4-chlorophenyl)thio]-4-[(diethylamino)sulfonyl]-7-methoxy-2-methyl-1*H*-indole-1-acetic acid;  
4-chloro-3-[(4-chlorophenyl)thio]-2-methyl-1*H*-indole-1-acetic acid;  
5-chloro-3-[(4-chlorophenyl)thio]-2-methyl-1*H*-indole-1-acetic acid;  
6-chloro-3-[(4-chlorophenyl)thio]-2-methyl-1*H*-indole-1-acetic acid;  
7-chloro-3-[(4-chlorophenyl)thio]-2-methyl-1*H*-indole-1-acetic acid;  
3-[(4-chlorophenyl)thio]-2-methyl-5-(methylsulfonyl)-1*H*-indole-1-acetic acid;  
2-methyl-3-[(4-methylphenyl)thio]-6-(methylsulfonyl)-1*H*-indole-1-acetic acid;  
4-bromo-3-[(4-chlorophenyl)thio]-2-methyl-1*H*-indole-1-acetic acid;  
3-[(4-chlorophenyl)thio]-4-[4-[(1,1-dimethylethoxy)carbonyl]-1-piperazinyl]-2-methyl-1*H*-indole-1-acetic acid;  
3-[(4-chlorophenyl)thio]-2-methyl-4-(1-piperazinyl)-1*H*-indole-1-acetic acid;  
5-bromo-3-[(4-chlorophenyl)thio]-2-methyl-1*H*-indole-1-acetic acid;  
3-[(4-chlorophenyl)thio]-2-methyl-5-phenyl-1*H*-indole-1-acetic acid;  
3-[(4-chlorophenyl)thio]-5-cyano-2-methyl-1*H*-indole-1-acetic acid;  
3-[(4-cyanophenyl)thio]-2,5-dimethyl-1*H*-indol-1-acetic acid,  
3-[(3-methoxyphenyl)thio]-2,5-dimethyl-1*H*-indole-1-acetic acid;  
3-[(4-methoxyphenyl)thio]-2,5-dimethyl-1*H*-indole-1-acetic acid,  
3-[(3-ethylphenyl)thio]-2,5-dimethyl-1*H*-indole-1-acetic acid  
2,5-dimethyl-3-[(2-methylphenyl)thio]-1*H*-indole-1-acetic acid;  
3-[(3-chlorophenyl)thio]-2,5-dimethyl-1*H*-indole-1-acetic acid,  
3-[(2-Fluorophenyl)thio]-2,5-dimethyl-1*H*-indole-1-acetic acid,  
3-[(2,6-Dichlorophenyl)thio]-2,5-dimethyl-1*H*-indole-1-acetic acid;  
3-(1*H*-Imidazol-2-ylthio)-2,5-dimethyl-1*H*-indole-1-acetic acid,  
2,5-Dimethyl-3-(1*H*-1,2,4-triazol-3-ylthio)-1*H*-indole-1-acetic acid;  
2,5-Dimethyl-3-[(4-methyl-4*H*-1,2,4-triazol-3-yl)thio]-1*H*-indole-1-acetic acid;  
2,5-Dimethyl-3-[(4-methyl-2-oxazolyl)thio]-1*H*-indole-1-acetic acid;  
2,5-Dimethyl-3-[(1-methyl-1*H*-imidazol-2-yl)thio]-1*H*-indole-1-acetic acid;  
2,5-Dimethyl-3-[[4-(methylsulfonyl)phenyl]thio]-1*H*-indole-1-acetic acid,  
2,5-Dimethyl-3-(8-quinolinylthio)- 1*H*-indole-1-acetic acid,  
3-[(4-Chlorophenyl)thio]-5-fluoro-2,4-dimethyl-1*H*-indole-1-acetic acid;  
3-[(4-Cyanophenyl)thio]-5-fluoro-2,4-dimethyl-1*H*-indole-1-acetic acid;

3-[(2-Chlorophenyl)thio]-5-fluoro-2,4-dimethyl-1*H*-indole-1-acetic acid;  
5-Fluoro-3-[(2-methoxyphenyl)thio]-2,4-dimethyl-1*H*-indole-1-acetic acid;  
5-Fluoro-3-[(2-ethylphenyl)thio]-2,4-dimethyl-1*H*-indole-1-acetic acid;  
5-Fluoro-2,4-dimethyl-3-[[2-(1-methylethyl)phenyl]thio]-1*H*-indole-1-acetic acid;  
5-fluoro-2,4-dimethyl-3-[[2-(trifluoromethyl)phenyl]thio]-1*H*-indole-1-acetic acid;  
2,5-dimethyl-4-(methylsulfonyl)-3-[(4-phenyl-2-thiazolyl)thio]-1*H*-indole-1-acetic acid;  
3-[(3-chlorophenyl)thio]-2,5-dimethyl-4-(methylsulfonyl)- 1*H*-indole-1-acetic acid;  
3-[(2-chlorophenyl)thio]-2,5-dimethyl-4-(methylsulfonyl)- 1*H*-indole-1-acetic acid;  
3-[(4-chlorophenyl)thio]-5-(methoxycarbonyl)-2-methyl-1*H*-indole-1-acetic acid;  
5-carboxy-3-[(4-chlorophenyl)thio]-2-methyl-1*H*-indole-1-acetic acid;  
3-[(4-chlorophenyl)thio]-2-methyl-4-nitro-1*H*-indole-1-acetic acid;  
4-amino-3-[(4-chlorophenyl)thio]-2-methyl-1*H*-indole-1-acetic acid;  
3-[(4-chlorophenyl)thio]-4-(ethylamino)-2-methyl-1*H*-indole-1-acetic acid;  
3-[(4-chlorophenyl)thio]-4-iodo-2-methyl-1*H*-indole-1-acetic acid;  
3-[(4-chlorophenyl)thio]-2-methyl-4-phenyl-1*H*-indole-1-acetic acid;  
and pharmaceutically acceptable salts thereof.

6-7. (Cancelled)


8. (Original) A method of treating according to claim 7 wherein the disease is asthma or rhinitis.

9. (Original) A process for the preparation of a compound of formula (I) which comprises reaction of a compound of formula (II):



(II)

in which  $R^1$ ,  $R^2$  and  $R^3$  are as defined in formula (I) or are protected derivatives thereof, with a compound of formula (A):



where  $R^{17}$  is an ester forming group and L is a leaving group in the presence of a base, and optionally thereafter in any order:

- removing any protecting group
- hydrolysing the ester group  $R^{17}$  to the corresponding acid forming a pharmaceutically acceptable salt.